Survodutide
What it is & what research shows
Study example availableSurvodutide is listed as a peptide in the metabolism section of this catalog. Also indexed as BI 456906. A source-verified explanation of its mechanism and uses has not yet been completed here; the catalog category is not evidence of benefit.
One selected study: A double-blind phase 3 trial compared survodutide with placebo for weight and glycemic outcomes. 752 adults with type 2 diabetes and BMI of at least 27. Subcutaneous survodutide 3.6 mg or 6.0 mg once weekly, versus placebo, over 76 weeks. For 3.6 mg, 6.0 mg, and placebo, respectively: weight changed -8.2%, -9.8%, and -3.9%; at least 5% weight loss occurred in 57.6%, 64.5%, and 35.1%. HbA1c fell 0.9, 0.8, and 0.2 percentage points. GI events occurred in 72.8%, 77.7%, and 38.6%, generally transient and mild to moderate. Treatment-regimen estimates include discontinuation or interruption. Placebo comparison cannot establish superiority to other incretins. Cardiovascular benefit and the glucagon pathway contribution were not established by these reported outcomes. Sponsor: Boehringer Ingelheim. Abstract assessment only. [2.1]
Sources & reading scope
- [2.1] Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.Human · Abstract summarized · not a full-paper review
Evidence summarized on PED Evidence
5 completed summaries
4 human-study reports
3 randomized-trial candidates
2 safety-topic reports
More about Survodutide: identity, safety & reference details
Also known as BI 456906
Start with the research
An outcome-specific synthesis has not been prepared for this compound. This is a coverage gap, not evidence that it has no effect.
Open studies and trial records- Uses & research
Uses have not been independently checked for this profile. Browse the original studies to see the conditions and populations investigated.
- Known half-life
No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.- Evidence & important limits
A catalog entry does not establish effectiveness, safety or approval. Study findings and quality appraisal remain separate.
Safety & evidence boundaries
A compound-specific safety synthesis is not available here yet. Lack of listed adverse effects does not establish safety.
Explore safety questions by system
These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.
Identity, names & formulations
Canonical compound: Survodutide · survodutide
Searchable names: BI 456906
Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.
Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.
Understand the evidence types
Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.
- Randomized human trials
- Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
- Controlled human studies
- Use a comparison group; allocation and confounding still matter.
- Prospective human research
- Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
- Observational human research
- Describes associations. Confounding can explain differences.
- Case reports and series
- Useful for unusual events and safety signals, not reliable rates or effect sizes.
- Animal research
- Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
- Cell and tissue research
- Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
- Mechanistic and computational evidence
- Helps explain or predict a pathway; predictions need experimental and clinical testing.
- Anecdotal reports
- Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.
Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.
Study model describes the source. Confidence depends on methods, replication, population and outcome.
Loading compound research…
Survodutide study summaries
Human-first reading order. Intervention candidates are distinguished from background mentions in the library.
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. · Human · 2024-06-07
- Dose-response effects on HbA<sub>1c</sub> and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. · Human · 2023-12-14
- Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes. · Human · 2026-10-01
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial. · Human · 2024-02-05
- Evaluation of Research Grade Peptides Marketed Directly to Consumers Reveals Extensive Variability in Purity and Measured Abundance · Preprint · 2026-04-24